基因表达与淋巴结阴性、雌激素受体阳性乳腺癌女性化疗获益的关系
在NSABP B20试验中检测651例肿瘤的21基因复发评分(RS),其中227例随机接受他莫昔芬、424例接受他莫昔芬联合化疗;化疗与RS交互作用检验有统计学意义(P=0.038),高RS(≥31)患者从他莫昔芬联合化疗中获益大,低RS(<18)患者获益极小甚至无获益。
要点
- 21基因复发评分(RS)可量化淋巴结阴性、雌激素受体阳性乳腺癌他莫昔芬治疗后的远处复发风险。
- 化疗与他莫昔芬联合化疗的交互作用检验有统计学意义(P=0.038),RS可预测化疗获益大小。
- 高RS(≥31)患者从他莫昔芬联合化疗中获益大,低RS(<18)患者获益极小甚至无获益。
核心结论
- 21基因复发评分(RS)不仅可量化淋巴结阴性、雌激素受体阳性乳腺癌女性的复发可能性,还可预测化疗获益的大小。
研究设计与样本
- 在NSABP B20试验中,检测接受他莫昔芬治疗及他莫昔芬联合化疗治疗患者的肿瘤RS,采用Cox比例风险模型检验化疗与RS的交互作用。
- 共651例患者可评估,其中227例随机分配至他莫昔芬组、424例随机分配至他莫昔芬联合化疗组。
主要发现
- 化疗与RS交互作用检验有统计学意义(P=0.038)。
- 高RS(≥31)肿瘤患者从他莫昔芬联合化疗中获益大:相对风险0.26(95%CI 0.13至0.53),10年远处复发率绝对下降均值27.6%(标准误8.0%)。
- 低RS(<18)肿瘤患者从他莫昔芬联合化疗中获益极小甚至无获益:相对风险1.31(95%CI 0.46至3.78),10年远处复发率绝对下降均值-1.1%(标准误2.2%)。
- 中等RS肿瘤患者似乎没有大的获益,但估计的不确定性不能排除有临床重要意义的获益。
局限性
- 中等RS肿瘤患者似乎没有大的获益,但估计的不确定性不能排除有临床重要意义的获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The 21-gene recurrence score (RS) assay quantifies the likelihood of distant recurrence in women with estrogen receptor-positive, lymph node-negative breast cancer treated with adjuvant tamoxifen. The relationship between the RS and chemotherapy benefit is not known. METHODS: The RS was measured in tumors from the tamoxifen-treated and tamoxifen plus chemotherapy-treated patients in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B20 trial. Cox proportional hazards models were utilized to test for interaction between chemotherapy treatment and the RS. RESULTS: A total of 651 patients were assessable (227 randomly assigned to tamoxifen and 424 randomly assigned to tamoxifen plus chemotherapy). The test for interaction between chemotherapy treatment and RS was statistically significant (P = .038). Patients with high-RS (≥ 31) tumors (ie, high risk of recurrence) had a large benefit from chemotherapy (relative risk, 0.26; 95% CI, 0.13 to 0.53; absolute decrease in 10-year distant recurrence rate: mean, 27.6%; SE, 8.0%). Patients with low-RS (< 18) tumors derived minimal, if any, benefit from chemotherapy treatment (relative risk, 1.31; 95% CI, 0.46 to 3.78; absolute decrease in distant recurrence rate at 10 years: mean, -1.1%; SE, 2.2%). Patients with intermediate-RS tumors did not appear to have a large benefit, but the uncertainty in the estimate can not exclude a clinically important benefit. CONCLUSION: The RS assay not only quantifies the likelihood of breast cancer recurrence in women with node-negative, estrogen receptor-positive breast cancer, but also predicts the magnitude of chemotherapy benefit.
引用
- Paik S, Tang G, Shak S, et al. Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer. J Clin Oncol. 2023. PMID: 37406456. doi:10.1200/JCO.22.02570
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。